A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer

Trial Profile

A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2018

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ANGEL
  • Sponsors LSK Biopharma
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 11 Jul 2018 Planned End Date changed from 30 Dec 2018 to 31 Mar 2019.
    • 11 Jul 2018 Planned primary completion date changed from 30 Aug 2018 to 28 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top